DK3882250T3 - Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser - Google Patents

Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser Download PDF

Info

Publication number
DK3882250T3
DK3882250T3 DK21165852.1T DK21165852T DK3882250T3 DK 3882250 T3 DK3882250 T3 DK 3882250T3 DK 21165852 T DK21165852 T DK 21165852T DK 3882250 T3 DK3882250 T3 DK 3882250T3
Authority
DK
Denmark
Prior art keywords
pyrrolopyrimidinone
btk
tetrahydropyranyl
amino
treatment
Prior art date
Application number
DK21165852.1T
Other languages
English (en)
Inventor
Jean-Marc Lapierre
Sudharshan Eathiraj
Nivedita Namdev
Brian Schwartz
Yusuke Ota
Takayuki Momose
Tomoyuki Tsunemi
Hiroaki Inagaki
Kiyoshi Nakayama
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Application granted granted Critical
Publication of DK3882250T3 publication Critical patent/DK3882250T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK21165852.1T 2015-12-23 2015-12-23 Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser DK3882250T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15911490.9A EP3394065B1 (en) 2015-12-23 2015-12-23 Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
PCT/US2015/000285 WO2017111787A1 (en) 2015-12-23 2015-12-23 Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
EP21165852.1A EP3882250B1 (en) 2015-12-23 2015-12-23 Tetrahydropyranyl amino-pyrrolopyrimidinone for use in treating btk-mediated disorders

Publications (1)

Publication Number Publication Date
DK3882250T3 true DK3882250T3 (da) 2023-05-22

Family

ID=59090991

Family Applications (2)

Application Number Title Priority Date Filing Date
DK21165852.1T DK3882250T3 (da) 2015-12-23 2015-12-23 Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK15911490.9T DK3394065T3 (da) 2015-12-23 2015-12-23 Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15911490.9T DK3394065T3 (da) 2015-12-23 2015-12-23 Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf

Country Status (28)

Country Link
EP (2) EP3882250B1 (da)
JP (1) JP6634520B2 (da)
KR (2) KR102547188B1 (da)
CN (2) CN113307811B (da)
AU (3) AU2015417922B2 (da)
CA (1) CA3008446C (da)
CY (1) CY1124210T1 (da)
DK (2) DK3882250T3 (da)
ES (2) ES2942743T3 (da)
FI (1) FI3882250T3 (da)
HR (2) HRP20230379T1 (da)
HU (2) HUE055221T2 (da)
IL (2) IL259938B (da)
LT (2) LT3394065T (da)
MA (1) MA56553B1 (da)
MD (1) MD3882250T2 (da)
MX (1) MX2018007815A (da)
MY (1) MY193177A (da)
PH (1) PH12018501390A1 (da)
PL (2) PL3394065T3 (da)
PT (2) PT3394065T (da)
RS (2) RS64141B1 (da)
RU (1) RU2715421C2 (da)
SA (1) SA518391836B1 (da)
SG (1) SG11201805154YA (da)
SI (2) SI3394065T1 (da)
WO (1) WO2017111787A1 (da)
ZA (1) ZA201804091B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019108280A (ru) 2016-08-24 2020-09-25 Аркьюл, Инк. Аминопирролопиримидиноновые соединения и способы их применения
CN109956870A (zh) * 2017-12-14 2019-07-02 南京卡文迪许生物工程技术有限公司 一种罗沙司他的合成方法及其中间体化合物
US20230357248A1 (en) * 2019-11-13 2023-11-09 Medshine Discovery Inc. Pyrrolopyrimidine compound as btk inhibitor and use thereof
CN112812100B (zh) * 2019-11-18 2022-04-05 四川海思科制药有限公司 一种具有降解btk激酶的化合物及其制备方法和药学上的应用
JP7011638B2 (ja) * 2019-12-16 2022-02-10 アークル インコーポレイテッド テトラヒドロピラニルアミノ-ピロロピリミジノンおよびその使用の方法
CN112608318B (zh) * 2019-12-16 2023-09-08 成都海博为药业有限公司 一种作为蛋白质激酶抑制剂的化合物及其用途
CN112574200B (zh) * 2021-02-26 2021-06-11 安润医药科技(苏州)有限公司 Btk和/或btk的突变体c481s的小分子抑制剂
CN115028633B (zh) * 2021-03-08 2023-12-22 药雅科技(上海)有限公司 吡咯并嘧啶类化合物的制备及其应用
CN114761410B (zh) * 2021-04-06 2023-08-25 广州必贝特医药股份有限公司 吡咯并嘧啶酮类化合物及其应用
WO2022213932A1 (zh) * 2021-04-06 2022-10-13 广州必贝特医药股份有限公司 吡咯并嘧啶酮类化合物及其应用
CN117794934A (zh) 2021-05-12 2024-03-29 浙江龙传生物医药科技有限公司 吡咯并嘧啶类化合物的晶型及其制备方法
WO2023110970A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Macrocyclic btk inhibitors
CN114409654A (zh) * 2021-12-30 2022-04-29 安徽普利药业有限公司 一种btk抑制剂的中间体合成方法
CN115894500A (zh) * 2022-11-02 2023-04-04 中国药科大学 一种作为btk激酶抑制剂的化合物及其制备方法与用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO2011063159A1 (en) * 2009-11-18 2011-05-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9012466B2 (en) * 2013-03-12 2015-04-21 Arqule Inc. Substituted tricyclic pyrazolo-pyrimidine compounds
JP6495886B2 (ja) * 2013-03-15 2019-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Btk阻害剤としての複素環式芳香族化合物
GB201309085D0 (en) * 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
GB201410430D0 (en) * 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds

Also Published As

Publication number Publication date
AU2019201737B2 (en) 2020-03-05
WO2017111787A1 (en) 2017-06-29
RU2715421C2 (ru) 2020-02-28
ES2942743T3 (es) 2023-06-06
CN108699062B (zh) 2021-06-29
MX2018007815A (es) 2019-07-04
JP6634520B2 (ja) 2020-01-22
CA3008446C (en) 2023-10-10
LT3394065T (lt) 2021-06-25
MA56553A (fr) 2022-04-27
RU2018126793A3 (da) 2020-01-23
PH12018501390A1 (en) 2019-02-27
CN108699062A (zh) 2018-10-23
PT3882250T (pt) 2023-04-21
MD3882250T2 (ro) 2023-06-30
HUE061761T2 (hu) 2023-08-28
SI3882250T1 (sl) 2023-07-31
AU2015417922A1 (en) 2018-06-28
BR112018012828A2 (pt) 2018-12-04
IL282572B (en) 2022-04-01
EP3394065B1 (en) 2021-04-07
RS64141B1 (sr) 2023-05-31
PT3394065T (pt) 2021-05-06
AU2015417922B2 (en) 2018-12-20
KR102547188B1 (ko) 2023-06-26
IL259938B (en) 2021-05-31
KR20180096753A (ko) 2018-08-29
AU2019201737A1 (en) 2019-04-04
PL3394065T3 (pl) 2021-08-02
EP3882250A1 (en) 2021-09-22
HUE055221T2 (hu) 2021-11-29
RU2018126793A (ru) 2020-01-23
MY193177A (en) 2022-09-26
AU2020203690A1 (en) 2020-06-25
IL282572A (en) 2021-06-30
HRP20210844T1 (hr) 2021-07-09
ZA201804091B (en) 2019-03-27
PL3882250T3 (pl) 2023-09-11
SI3394065T1 (sl) 2021-08-31
ES2868884T3 (es) 2021-10-22
FI3882250T3 (fi) 2023-04-27
AU2020203690B2 (en) 2021-08-05
DK3394065T3 (da) 2021-05-31
RS61887B1 (sr) 2021-06-30
MA56553B1 (fr) 2023-04-28
JP2018538349A (ja) 2018-12-27
KR20230098690A (ko) 2023-07-04
SG11201805154YA (en) 2018-07-30
CA3008446A1 (en) 2017-06-29
CY1124210T1 (el) 2022-05-27
SA518391836B1 (ar) 2022-06-19
EP3882250B1 (en) 2023-02-15
HRP20230379T1 (hr) 2023-06-23
CN113307811A (zh) 2021-08-27
LT3882250T (lt) 2023-05-25
EP3394065A1 (en) 2018-10-31
EP3394065A4 (en) 2019-07-10
IL259938A (en) 2018-07-31
CN113307811B (zh) 2023-11-14

Similar Documents

Publication Publication Date Title
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK3570844T3 (da) Azolopyrimidin til behandlingen af kræftrelaterede lidelser
DK3334422T3 (da) Anvendelse af cannabidiolsyre i behandling af epilepsi
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
DK3206715T3 (da) Anvendelse af cannabidiol i behandling af tuberøs sklerosekompleks
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3521282T3 (da) Quinazolinderivater anvendt til behandling af hiv
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3102213T3 (da) Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK3524255T3 (da) Sammensætning til behandling af acne
DK3391902T3 (da) Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3204038T3 (da) Sammensætninger omfattende amylase til anvendelse i behandlingen af pruritus
DK3328864T3 (da) Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser
DK3253208T3 (da) Kombinationsterapier til anvendelse i behandlingen af brystcancer
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme